JAMA Oncology

Papers
(The H4-Index of JAMA Oncology is 74. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Analysis of Outcomes With Addition of Immunotherapy to Chemoradiation Therapy for Non–Small Cell Lung Cancer—Reply1139
Coding Error in Study Evaluating Eligibility of US Black Women Under USPSTF Lung Cancer Screening Guidelines373
Reducing the Risks of Nuclear War—The Role of Health Professionals324
JAMA Network Call for Papers on Health and the 2024 US Election319
Active Surveillance for Low-risk Papillary Thyroid Carcinoma—Reply289
JAMA Oncology Peer Reviewers in 2022278
Metformin—A Thought-provoking Addition to Anticancer Therapies262
Error in Funding/Support253
Lower Back Pain in a Patient With Sarcoma249
Tissue-Based PD-L1 Expression Is the Strongest Predictor of Overall Survival Benefit From ICI in Advanced Gastroesophageal Cancer—Reply231
Prone Whole-Breast Radiotherapy—Better Than Supine?229
Errors in Byline and Affiliations223
Errors in Byline222
Evidence Base on the Potential Carcinogenicity of Radiofrequency Radiation214
Interpretation of the Efficacy of Multidisciplinary Geriatric Assessment Intervention on Chemotherapy-Related Toxic Effects in Older Adults With Cancer—Reply213
Insights Into Immune-Mediated Disease and Cancer Risk—Delivering on the Promise of UK Biobank Big Data197
Considerations in Narrowing the Breast Cancer Mortality Gap Between Black and White Women183
JAMA Oncology179
A Radiation Oncologist’s Experience With Medical Aid in Dying175
JAMA Oncology174
JAMA Oncology Peer Reviewers in 2020166
Error in Results and Table 1164
A Partnership to Advance Care of Patients With Acute Promyelocytic Leukemia164
Nivolumab + Ipilimumab as Immunotherapeutic Boost in Metastatic Urothelial Carcinoma162
Assessment of Response to a Third Dose of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Patients With Solid Tumors Undergoing Active Treatment160
Methodology Concerns Regarding Claims Data Studies in Transgender Health—Reply158
High-risk Medulloblastoma—Balancing the High Stakes of Molecular Profiling to Enhance Treatment Responsivity154
On Diction152
Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant147
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma135
Local Immunoradiotherapy in Patients With Metastatic Soft-Tissue Sarcoma135
Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer and Response to Checkpoint Inhibition135
Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia133
Intensity-Modulated Reirradiation Therapy With Nivolumab in Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma128
Vaccinia (Smallpox) for the Treatment of Ovarian Cancer—Turning an Old Foe Into a Friend?124
Assessment of a Contralateral Esophagus–Sparing Technique in Locally Advanced Lung Cancer Treated With High-Dose Chemoradiation123
Forging a Path for Metformin Use in Inoperable Locally Advanced Non–Small Cell Lung Cancer122
To Treat or Not to Treat Men With Low-risk or Intermediate-risk Prostate Cancer—Weighing the Evidence121
Association of Adjuvant Immunotherapy Duration With Chronic Immune-Related Adverse Events120
JAMA Oncology113
Errors in Title, Abstract, Methods, and Visual Abstract109
Is Pertuzumab Plus Trastuzumab Without Chemotherapy a Reasonable Treatment for ERBB2-Positive Metastatic Breast Cancer?—Reply105
Association of Antineoplastic Therapy With Decreased SARS-CoV-2 Infection Rates in Patients With Cancer105
Mortality and Hospitalization Risks in Patients With Cancer and the SARS-CoV-2 Omicron Variant104
Association of Radiation and Procarbazine Dose With Risk of Colorectal Cancer Among Survivors of Hodgkin Lymphoma102
Error in a Supplement101
Unlocking the Potential of Anti-TIGIT Therapy—Between Promise and Challenges101
Concerns Regarding the Utility of High-Risk Pancreatic Cancer Surveillance—Reply100
More on Waterpipe Tobacco Smoking and Cancer Mortality Content —Reply100
Concerns Regarding the Utility of High-Risk Pancreatic Cancer Surveillance98
FOLFOX/FOLFIRI–Bevacizumab for Unresectable Colorectal Liver Metastases97
Circulating Tumor DNA as Measurable Residual Disease in Aggressive B-Cell Lymphoma97
Biomarker Analysis of Vistusertib Plus Paclitaxel Regimen—Reply96
JAMA Oncology96
Stargazers95
Risk of Death Due to Pregnancy-Associated Cancers—More Questions Than Answers93
Biomarker Analysis of Vistusertib Plus Paclitaxel Regimen90
PSMA PET in Prostate Cancer—A Biomarker or a Surrogate End Point?—Reply89
Ending One’s Life Is Not Always a Sign of Psychopathology—Reply89
Hypofractionated Radiotherapy for Locally Advanced Non–Small Cell Lung Cancer—Does Size Matter?—Reply87
Errors in Data and Language87
Quantifying the Long-term Survival Benefit of Pembrolizumab for Patients With Advanced Gastric Cancer87
What Is the Optimal Treatment for Vulnerable Older Women With Ovarian Cancer?87
Stereotactic Ablative Body Radiotherapy for Metastases Needs Better Evidence83
Randomized Clinical Trials in the Era of Precision Oncology—The Role of End Points, Industry Funding, and Medical Writing Integrity82
Error in Visual Abstract80
Is Pertuzumab Plus Trastuzumab Without Chemotherapy a Reasonable Treatment for ERBB2-Positive Metastatic Breast Cancer?80
Considerations in Meta-Analysis of Immunotherapy for Advanced Cancers Other Than Melanoma80
Information Blocking and Oncology80
Errors in Reported Primary and Secondary Outcomes and Table Numbers in a Trial of Radiotherapy for Pain Relief in Patients With Bone Metastases78
Error in Article Title78
Is 2045 Optimistic?—Concerns Regarding Rising Vaccine Hesitancy77
Evaluating Eligibility of US Black Women Under USPSTF Lung Cancer Screening Guidelines76
Caution With Routine Use of Daratumumab for Newly Diagnosed High-Risk Multiple Myeloma76
Deciphering Genomic Risk in Prostate Cancer—Ready for Prime Time74
Induction Chemotherapy for Advanced Nasopharyngeal Carcinoma—Is This the New Standard of Care?74
Misinterpretation of Surgeons’ Statements on Cancer Removal—The Adverse Effects of “We Got It All”74
Risk, Racial Disparity, and Outcomes Among Patients With Cancer and COVID-19 Infection—Reply74
0.038355827331543